Plain-English translation of NCT04428554 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a focused radiation treatment called consolidative radiotherapy can help people with advanced bladder cancer live longer. You would be eligible if your cancer has responded well to initial chemotherapy or immunotherapy and you have only a few remaining cancer spots. The study compares two groups: one receiving standard care alone, and one receiving standard care plus targeted radiation therapy to the remaining cancer lesions.
Many patients with advanced bladder cancer have a good response to chemotherapy or immunotherapy, but still have a few remaining cancer spots that could potentially be eliminated with radiation. This trial is trying to find out whether adding this focused radiation treatment can improve survival and help more patients beat their disease.
You likely qualify if…
You likely don't qualify if…
After you finish your initial chemotherapy or immunotherapy and if your cancer responds well, you will be randomly assigned to either continue standard care alone or to receive standard care plus targeted radiation therapy to your remaining cancer spots. You will be followed for 4 years from the date you are randomly assigned, with regular check-ups and imaging scans to monitor how you are doing. The radiation treatment would be delivered over several sessions at a specialized cancer center.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France